Saleh Samer, Ghodsian Shahriar, Yakimova Violeta, Henderson John, Sharma Om P
Department of Medicine, Pulmonary & Critical Care Division, University of Southern California, 1200N, State St., GNH 11900, Los Angeles, CA 90033, USA.
Respir Med. 2006 Nov;100(11):2053-9. doi: 10.1016/j.rmed.2006.02.017. Epub 2006 Aug 28.
To assess the effectiveness of infliximab (Remicade) in the treatment of patients with sarcoidosis who either do not respond to corticosteroids and other conventional drugs or develop unacceptable side effects to these drugs.
A clinical, non-randomized, off-label study.
Sarcoidosis clinic at a university teaching hospital.
Twelve biopsy-proven sarcoidosis patients, nine women and three men ranging from 45 to 70 years of age with chronic multisystem sarcoidosis refractory to corticosteroids or alternative treatment.
Infliximab was infused at a dedicated ambulatory infusion center. The initial dose was 3mg/kg body weight and subsequent doses were given at weeks 2, 4, 6, 10, and 14. All patients received at least six infusions.
All 12 patients improved significantly. One patient had a mild allergic drug reaction that responded to antihistamine. One patient, after 3 months of stopping infliximab treatment, died of a ruptured blood vessel in the abdomen. At autopsy a plasma cell dyscrasia was found.
Infliximab is safe and effective in treating those patients with multisystem sarcoidosis who are either refractory or develop side effects to a standard regimen of corticosteroids and immunosuppressive agents.
评估英夫利昔单抗（类克）对那些对皮质类固醇及其他传统药物无反应或出现不可接受的药物副作用的结节病患者的治疗效果。
一项临床、非随机、非标签研究。
一所大学教学医院的结节病诊所。
12例经活检证实的结节病患者，9名女性和3名男性，年龄在45至70岁之间，患有对皮质类固醇或替代治疗无效的慢性多系统结节病。
在专门的门诊输液中心输注英夫利昔单抗。初始剂量为3mg/kg体重，后续剂量在第2、4、6、10和14周给药。所有患者至少接受6次输注。
所有12例患者均有显著改善。1例患者出现轻度药物过敏反应，对抗组胺药有反应。1例患者在停止英夫利昔单抗治疗3个月后死于腹部血管破裂。尸检发现浆细胞异常增生。
英夫利昔单抗在治疗那些对皮质类固醇和免疫抑制剂标准治疗方案难治或出现副作用的多系统结节病患者中是安全有效的。
